Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Ministers cannot be the last to know when inward investors like Zimmer Biomet pull out of Wales

A more constructive approach to managing relationships with major employers is important in the future especially if they are in receipt of public funding.

Birmingham Post

RSS’s pharma body writes to Health Ministry criticising risk-based inspections, backtracks later

In a strongly worded letter to the Union Health Ministry, the Rashtriya Swayamsewak Sangh- (RSS) backed Laghu Udyog Bharati, which represents over 300 micro and small industries across India, has said the Union government’s risk-based inspections (RBI) on pharma companies were draconian and have been a huge discouragement to the…

The Hindu

AbbVie (ABBV) vs. Pfizer (PFE) - Which Pharma Stock Comes out on Top?

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna signs deal to make mRNA vaccines for Chinese market

Moderna Inc. will push toward producing messenger RNA vaccines for China, seeking a foothold in the world’s second-largest pharmaceutical market even as geopolitical tensions rise.

Tribune News Service

Regulation for all medical devices from October 1, says DCGI

India is on course to introduce regulations governing all the medical devices in the country on October 1, Drugs Controller General of India Rajeev Singh Raghuvanshi said at iPhex 2023

The Hindu

Condom maker’s success boosts hopes of more consumer IPOs in India

MUMBAI: The stellar performance of Mankind Pharma Ltd since its listing in Mumbai in May could trigger more consumer-related initial public offerings in India in the second half, according to bankers.

The Times of India

Which Pharma Stock Is the Better July Pick: Johnson & Johnson (JNJ) or Curaleaf Holdings (CURLF)?

On the backs of increasing medical requirements amid the soaring incidence of chronic diseases, the pharmaceutical industry’s outlook radiates promise. Given this backdrop, let us compare pharma stocks Johnson & Johnson (JNJ) and Curaleaf Holdings (CURLF) to discover which one of these could be worth buying in July. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Medicare To Negotiate Drug Prices, Lower Costs

CMS releases guidance on using authority to expand benefits, reduce drug costs, and strengthen Medicare program.

Zenger

Pharmacies receive $377m medication sweetener

Pharmacies will be paid thousands more to dispense medicines from July 1 as part of a government funding boost.

AAP

Will lower-cost Humira pharmaceutical options soon be available to patients?

Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings?

Tribune News Service

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Tribune News Service

Is Catalyst Pharmaceuticals (CPRX) a Quality Investment?

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) delivered a robust performance in the first quarter of 2023. However, it fell short of analysts’ estimates. Let’s dig into some of its financial metrics to determine whether CPRX is worth buying ahead of the upcoming earnings season.

StockNews.com

Deep concern as Zimmer Biomet closure in Bridgend puts 540 jobs at risk

The announcement has left a community in shock

Wales Online

Andor Technologies sets sights on £20M of exports with new scientific microscope

The company said the new product represents disruptive technology and will see it break into new markets

Birmingham Post

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

Birmingham Post

Hundreds of jobs at threat at South Wales hip replacement factory

Zimmer Biomet has confirmed plans to close its factory in Bridgend

Wales Online

540 jobs at risk as Bridgend Zimmer Biomet plant set to close

Zimmer Biomet in Bridgend has entered into consultation with its staff

The Hindu

India takes first step to remove animals from drug-testing process

Every drug in the market goes through a long journey of tests, each designed to check whether it can treat the disease for which it was created and whether it has any unintended harmful effects. For a long time, the first step of this process was to test the candidate…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

2 Biotech Stocks to Buy, 1 to Sell Now

The biotech industry is well-positioned for long-term growth thanks to increasing demand for quality healthcare, a rapidly aging population, and rising chronic diseases. Therefore, buying fundamentally strong biotech stocks Entrada Therapeutics (TRDA) and ProQR Therapeutics N.V. (PRQR) could be wise. On the other hand, one should consider selling 4D Molecular…

StockNews.com

3 Medical Stocks to Buy for Great Value

Owing to the rising prevalence of chronic medical conditions and awareness among the patient population, the medical industry is poised for remarkable growth. Therefore, it could be wise to scoop up the shares of quality medical stocks Medtronic plc (MDT), FONAR Corporation (FONR), and Electromed, Inc. (ELMD), which carry significant…

StockNews.com

3 Biotech Stocks With Some Major Value in Them

The worldwide need for healthcare and biotech products is experiencing a steady upsurge fueled by various factors, such as a heightened emphasis on personalized medicine. Therefore, it could be wise to explore three quality biotech stocks, Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS), with significant value in them. Read…

The Conversation

Canada's misguided changes to drug regulation could fast-track unproven medications and divert funds from other health needs

The Canadian government is proposing a new “Agile Licensing” framework to expedite pre-market regulation of pharmaceuticals. While Health Minister Jean-Yves Duclos claims this is part of the government’s strategy to offer Canadians “access to quality and affordable medicines,” the policy is likely to cause more harm than good.

Zenger

Moderna Stock Rises After FDA Application For Updated Vaccine

Moderna's potential beyond COVID-19 is underappreciated, says analyst Eliana Merle, who upgraded the stock to Buy

Birmingham Post

North East deals of the week: key acquisitions, contracts and investments

Companies featuring in this week's round-up include Max Purpose Psychology, Parker Bioscience Filtration, Ward Investments Group, Newcastle Building Society and Talk Works

Radio France Internationale

Should France guarantee supply of abortion drugs by producing its own?

One of two abortion pills has been added to the list of drugs France considers essential, but it is not among 50 medications that President Emmanuel Macron says will soon be produced locally – even despite a recent shortage that raised questions about France's ability to guarantee the right to…

1 … 46 47 48 49

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Mark Butler

564 stories

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.